Data / Drug companies / Zhejiang Huahai Pharmaceutical Co., LTD.
Zhejiang Huahai Pharmaceutical Co., LTD.: 82 products in the FDA NDC directory, labeler code 64220
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Zhejiang Huahai Pharmaceutical Co., LTD. (labeler code 64220) lists 82 products in the FDA National Drug Code Directory. By type: 82 bulk ingredients. Its main marketing category is bulk ingredients. The newest product started marketing on August 28, 2026.
The request: Watch Zhejiang Huahai Pharmaceutical Co., LTD. (FDA labeler code 64220): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 64220
- Products in commercial distribution
- 82
- Packages
- 682
- Finished drugs by generic name
- 0
- Prescription products
- 0
- Over the counter products
- 0
- Controlled substance products
- Schedule V 2
- Started marketing in the last 12 months
- 5
- Earliest marketing start
- December 1, 2005
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Bulk ingredients | 78 | 95.1% |
| Bulk ingredients for compounding | 4 | 4.9% |
Products by type
| Type | Products | Share |
|---|---|---|
| Bulk ingredients | 82 | 100% |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Powder | 80 | 97.6% |
| Tablet | 2 | 2.4% |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Blend for valsartan tablets | 64220-992 | Powder | Bulk ingredients for compounding | August 28, 2026 |
| Quetiapine fumarate | 64220-702 | Powder | Bulk ingredients | March 26, 2026 |
| Finerenone | 64220-708 | Powder | Bulk ingredients | March 12, 2026 |
| Perindopril arginine | 64220-227 | Powder | Bulk ingredients | March 4, 2026 |
| Vortioxetine hydrobromide | 64220-701 | Powder | Bulk ingredients | March 2, 2026 |
| Rivaroxaban | 64220-228 | Powder | Bulk ingredients | August 14, 2025 |
| Oseltamivir phosphate | 64220-217 | Powder | Bulk ingredients | May 13, 2025 |
| Dimethyl fumarate | 64220-198 | Powder | Bulk ingredients | February 5, 2025 |
| Ambrisentan | 64220-156 | Powder | Bulk ingredients | January 8, 2025 |
| Gabapentin | 64220-700 | Powder | Bulk ingredients | December 4, 2024 |
| Sertraline hydrochloride | 64220-224 | Powder | Bulk ingredients | September 23, 2024 |
| Entecavir | 64220-160 | Powder | Bulk ingredients | September 3, 2024 |
| Tofacitinib citrate | 64220-210 | Powder | Bulk ingredients | August 19, 2024 |
| Brexpiprazole | 64220-205 | Powder | Bulk ingredients | August 19, 2024 |
| Apremilast | 64220-200 | Powder | Bulk ingredients | August 14, 2024 |
| Levomilnacipran hydrochloride | 64220-190 | Powder | Bulk ingredients | August 14, 2024 |
| Metoprolol succinate | 64220-165 | Powder | Bulk ingredients | August 4, 2024 |
| Agomelatine | 64220-223 | Powder | Bulk ingredients | July 30, 2024 |
| Dapagliflozin propanediol (process ii) | 64220-221 | Powder | Bulk ingredients | July 30, 2024 |
| Sacubitril valsartan sodium | 64220-222 | Powder | Bulk ingredients | July 23, 2024 |
| Ketotifen fumarate | 64220-146 | Powder | Bulk ingredients | June 4, 2024 |
| Apixaban | 64220-185 | Powder | Bulk ingredients | April 12, 2024 |
| Brivaracetam | 64220-191 | Powder | Bulk ingredients | October 24, 2023 |
| D-2,3-diaminopropionic acid hydrochloride | 64220-219 | Powder | Bulk ingredients | August 1, 2023 |
| Azelaic acid | 64220-204 | Powder | Bulk ingredients | August 1, 2023 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.